Magnetic Peripheral Nerve Stimulation (mPNS) for Back Pain
SAN DIEGO, August. 6, 2025 – Neuralace Medical today announced the presentation of a compelling case report at the American Society of Pain & Neuroscience (ASPN) Annual Conference, showcasing the successful use of Axon Therapy®, a non-invasive magnetic peripheral nerve stimulation (mPNS) technology in treating chronic low back pain unresponsive to conventional medical management (CMM).
The abstract, authored by Marshall D. Bedder, MD, and Lisa Parker, NP, outlines the treatment of a 37-year-old male patient with a disc herniation at L5-S1 causing persistent, localized back pain. After failing conventional therapies such as TENS, acupuncture, and topical medications, the patient underwent six Axon Therapy sessions over 50 days. At follow-up, he reported a 60% reduction in pain on the Visual Analog Scale (VAS), along with marked improvements in function, including a return to the gym and the ability to bend at the waist—a task previously limited by pain.
“This case reinforces the potential of non-invasive neuromodulation to restore function and reduce pain for patients with disc-related chronic low back pain,” said Dr. Bedder.
Axon Therapy targets the dorsal root ganglion (DRG), a key hub in the peripheral nervous system, using magnetic stimulation to modulate pain signals noninvasively¹. The platform is FDA-cleared for the treatment of chronic intractable pain, including painful diabetic neuropathy (PDN), post-surgical, and post-traumatic neuropathic pain. There are no leads, no injections, no surgical implants, no risks of infection, and no therapy interruptions due to lead fracture or battery failure.
The case study complements growing evidence from recent peer-reviewed trials demonstrating mPNS efficacy across multiple chronic neuropathic pain conditions. For instance, Bedder and Parker previously published clinical findings supporting the use of mPNS for chronic pain², while larger randomized controlled studies have validated Axon Therapy’s use in treating painful diabetic neuropathy and post-traumatic neuropathy³⁻⁴.
“When we stimulate the DRG using magnetic pulses, we’re tapping into a new way to modulate pain without drugs, needles, or implants,” said Lisa Parker, NP. “This may change how we approach certain spine-related pain syndromes going forward.”
This report adds to the growing body of literature on mPNS as a non-medication, non-interventional, and painless therapy for chronic neuropathic pain including post-operative and diabetic neuropathy. It also positions mPNS as a viable alternative in cases of herniated disc disease that may otherwise require escalation to invasive treatments³⁻⁴.
For more information about Axon Therapy and its benefits, visit neuralacemedical.com.
For media inquiries or more information about Neuralace Medical and its groundbreaking research, please contact:
Chris Morano, Vice President of Sales
[email protected]
About Neuralace Medical
Neuralace Medical is a pioneering medical technology company committed to advancing safe, non-invasive solutions for chronic neuropathic pain. Founded by a team of creative and resolute professionals, the company has developed Axon Therapy®, the first and only FDA-cleared magnetic peripheral nerve stimulation (mPNS) platform. It delivers the benefits of neuromodulation without the need for ablation, injection, or surgery. Originally introduced in VA clinics to serve Veterans with chronic pain, Axon Therapy has now been used in over 5,000 clinical treatments. Neuralace Medical is expanding access to its breakthrough electroceutical platform, offering a drug-free and needle-free option for patients seeking meaningful relief from chronic nerve-related pain.
For more information visit www.neuralacemedical.com
References:
- Ahimsadasan N, Reddy V, Khan Suheb MZ, et al. Neuroanatomy, Dorsal Root Ganglion. [Updated 2022 Sep 21]. In: StatPearls [Internet]. StatPearls Publishing; 2025.
- Bedder M, Parker L. Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain. J Pain Res. 2023;16:2365–2373.
- Kapural L, et al. SEAT Study: Safety and Efficacy of Axon Therapy (mPNS) for Neuropathic Pain. J Pain Res. 2024;17:3167–3174.
- Brown L. Double-Blind RCT: Axon Therapy vs. Sham for Painful Diabetic Neuropathy. Neuromodulation. 2024;27(S7):S275.
